Catalist-listed SeD claims its two compounds can block Covid-19 infection

Tue, Mar 17, 2020 - 9:38 PM

Natalie Choychoycmn@sph.com.sg@NatalieChoy

CATALIST-LISTED Singapore eDevelopment (SeD) on Tuesday said that its US subsidiary, Impact BioMedical, has tested two compounds that can successfully inhibit the infection by the Covid-19 virus.

Results from Impact BioMedical's recent molecular-docking studies indicate that compounds '...

To continue reading

for full content

if you are a subscriber

Get our introductory offer at only

$0 .99*/month

Cancel anytime

*$0.99/month for first 3 months

$29.90/month for the next 9 months

Need help?

CALL +65 6388 3838 EMAIL btocs@sph.com.sg

OPERATING HOURS (+8 GMT) MON-FRI: 8:30AM-5:30PM

Register to read this article. Log in if you are already a subscriber. Register to read this article. Log in if you are already a subscriber. Please log in or subscribe to continue reading.